Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Regulatory Officer | February 23, 2026 | February 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date February 23, 2026 · Filed February 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 45,313 |
Reported balance
After 2026-02-23 transaction · row 1
1 source rowRow 1 · 2026-02-23 · Sale · Disposed 2,187 · Balance 45,313 F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026.
F2: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.
F3: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 · Expires 2030-08-04 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option vested as to 25% of the total shares on August 4, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 49,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.73 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 12,300 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.54 · Expires 2032-03-14 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the total shares on August 4, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F3: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
F4: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
F5: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2026 Filed Feb 25, 2026 19:56 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 2,187 | $41.98 | $91,818.79 |
DisclosureSEC source: 0001819688-26-000005 · form4-02262026_120218.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,313 F1 · date: The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026. F2 · kind: Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 20:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $42.74 | $0.00 |
DisclosureSEC source: 0001819688-26-000002 · form4-02062026_080205.xml · derivative · entry 2 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2036-02-03 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 20:00 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001819688-26-000002 · form4-02062026_080205.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001193125-25-322691 · ownership.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,000 Underlying: Class A Common Stock · 10,000 shares Expires 2034-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,000 | $50.08 | $500,767.00 |
DisclosureSEC source: 0001193125-25-322691 · ownership.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.00 to $50.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $15.53 | $155,300.00 |
DisclosureSEC source: 0001193125-25-322691 · ownership.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001193125-25-314156 · ownership.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,000 Underlying: Class A Common Stock · 10,000 shares Expires 2034-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,000 | $45.31 | $453,053.00 |
DisclosureSEC source: 0001193125-25-314156 · ownership.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $45.00 to $45.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $15.53 | $155,300.00 |
DisclosureSEC source: 0001193125-25-314156 · ownership.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001193125-25-308074 · ownership.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,000 Underlying: Class A Common Stock · 10,000 shares Expires 2034-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001193125-25-308074 · ownership.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | Exercise / conversionClass A Common Stock | 10,000 | $15.53 | $155,300.00 |
DisclosureSEC source: 0001193125-25-308074 · ownership.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:11 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001415889-25-004849 · form4-02202025_090246.xml · derivative · entry 2 Turner William D. · CIK 0001819688 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2035-02-17 F2 · derivative.exercise_date: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 16:11 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004849 · form4-02202025_090246.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001209191-24-001231 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Class A Common Stock · 275,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:32 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-040244 · doc4.xml · derivative · entry 4 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2032-03-14 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F5 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:32 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 12,300 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-22-040244 · doc4.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,300 shares Expires 2031-03-15 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4 · derivative.exercise_date: The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:32 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 49,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-040244 · doc4.xml · derivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,000 shares Expires 2030-08-12 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3 · derivative.exercise_date: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:32 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-040244 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2030-08-04 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1 · derivative.exercise_date: The option vested as to 25% of the total shares on August 4, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 16:17 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-037850 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F1 · date: On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,347 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · derivative · entry 6 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,347 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 6,347 | $37.25 | $236,409.25 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · nonDerivative · entry 4 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 6,347 | $12.05 | $76,481.35 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · nonDerivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · derivative · entry 5 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 100 | $37.09 | $3,709.00 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 16:12 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 100 | $12.05 | $1,205.00 |
DisclosureSEC source: 0001209191-22-023656 · doc4.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 16:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-020521 · doc4.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 16:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 100 | $37.05 | $3,705.00 |
DisclosureSEC source: 0001209191-22-020521 · doc4.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 16:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 100 | $12.05 | $1,205.00 |
DisclosureSEC source: 0001209191-22-020521 · doc4.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 18:33 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,453 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-019748 · doc4.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,453 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 18:33 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 3,453 | $37.06 | $127,953.68 |
DisclosureSEC source: 0001209191-22-019748 · doc4.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| March 17, 2022 Filed Mar 17, 2022 18:33 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 3,453 | $12.05 | $41,608.65 |
DisclosureSEC source: 0001209191-22-019748 · doc4.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 14, 2022 16:42 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $31.54 | $0.00 |
DisclosureSEC source: 0001209191-22-018485 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:03 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-007719 · doc4.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:03 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 10,000 | $32.32 | $323,225.00 |
DisclosureSEC source: 0001209191-22-007719 · doc4.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:03 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 10,000 | $12.05 | $120,500.00 |
DisclosureSEC source: 0001209191-22-007719 · doc4.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2022 Filed Jan 28, 2022 16:39 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,250 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005426 · doc4.xml · derivative · entry 4 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2030-08-12 F3 · date: On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 16:39 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-22-005426 · doc4.xml · derivative · entry 3 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2030-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 16:39 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | SaleCommon Stock | 5,000 | $27.05 | $135,250.00 |
DisclosureSEC source: 0001209191-22-005426 · doc4.xml · nonDerivative · entry 2 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 23, 2022. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 16:39 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Exercise / conversionCommon Stock | 5,000 | $12.05 | $60,250.00 |
DisclosureSEC source: 0001209191-22-005426 · doc4.xml · nonDerivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:18 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 12,300 | $0.00 Strike: $16.73 | $0.00 |
DisclosureSEC source: 0001209191-21-021625 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 18:52 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001209191-20-045576 · doc4.xml · derivative · entry 1 Turner William D. · CIK 0001819688 · Chief Reg & Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-04 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on August 4, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.